All In Biotech

Drug Trial Radar · NCT04540770

A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HuL001

A Phase 1 Single and Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HuL001 in Healthy Volunteers and Idiopathic Pulmonary Fibrosis Subjects

Last checked: Nov 19, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Aug 31, 2021

Primary completion

Mar 4, 2022

Study completion Jan 19, 2024

Sponsor

Lead sponsor
HuniLife Biotechnology, Inc.Industry
Sponsor type
Industry
First posted
Sep 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a first-in-human, two-part, Phase 1 study that will characterize the safety, tolerability, PK, and immunogenicity of HuL001.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • HuL001Drug

    Anti-ENO1 monoclonal antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency, severity, and causality of adverse events (AEs), including solicited local AEsTime frame: 70 Days in Part A and 84 Days in Part B
  2. Proportion of subjects who report clinically significant abnormal findings in physical examinationTime frame: 70 Days in Part A and 84 Days in Part B
  3. Change from baseline in blood pressureTime frame: 70 Days in Part A and 84 Days in Part B
  4. Change from baseline in respiratory rateTime frame: 70 Days in Part A and 84 Days in Part B
  5. Change from baseline in heart rateTime frame: 70 Days in Part A and 84 Days in Part B
  6. Change from baseline in body temperatureTime frame: 70 Days in Part A and 84 Days in Part B
  7. Change from baseline in hematology assessmentsTime frame: 70 Days in Part A and 84 Days in Part B
  8. Change from baseline in biochemistry assessmentsTime frame: 70 Days in Part A and 84 Days in Part B
  9. Change from baseline in electrocardiogram (ECG) results (including PR, QRS, QT, QTcF, and RR intervals)Time frame: 70 Days in Part A and 84 Days in Part B
  10. Tolerability of HuL001 in terms of frequency of events meeting the intra-cohort stopping criteria within the tolerability observation periodTime frame: 70 Days in Part A and 84 Days in Part B

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Mackay Memorial Hospital

    New Taipei City, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.